Last checked at (Sharecast News) - Medical equipment supplier Deltex said on Wednesday that the Covid-19 pandemic had provided "an external stimulus" to drive higher adoption rates of its TrueVue Doppler technology in intensive care units.
Deltex said revenues for its critical care probe devices had increased "significantly" during March and April, especially in the UK. However, the group warned that ICU demand had been offset by a "significant reduction" of operating room-related revenues, as hospitals dramatically curtailed admitting patients for elective surgery.
But the AIM-listed group stated that as the number of Covid-19 patients requiring hospitalisation was continually decreasing, hospitals were now moving to restart elective surgery.
"At the moment it is too early to determine what proportion of the reduction in OR-related revenues experienced through the first half will be caught up later in the year. Nor is it possible to assess how large demand will be this year for TrueVue Doppler (and other modalities on its TrueVue haemodynamic monitoring system) in the ICU setting," said chairman Nigel Keen at the group's closed-door annual general meeting.
"However, it is already clear that, where Covid-19 patients are being treated, there is increased demand for the group's TrueVue Doppler."
As of 0945 BST, Deltex shares were down 3.10% at 1.60p.
16 Sep 2015 09:51
Deltex stocks fall on back on first half losses
(ShareCast News) - Deltex Medical Group's stocks plunged Wednesday morning after reporting wider first-half losses. The company, which manufactures and markets oesophageal Doppler monitoring, released their first half results to 30 June 2015. They posted an operating loss of £2.1m, down from £1.5m
Read more